As per the agreement, both the companies will jointly work and organize research for the discovery of DDS technology for RNAi therapeutics based on Samyang’s technology in three years, and more if necessary.
The terms of the contract entitled Samyang to get an upfront payment to Takeda, who will also bear research costs during the collaboration period.
Samyang is also eligible to receive milestone payments and sales-based royalties from Takeda.
Samyang Bio & Pharmaceuticals Group COO Cheolho Kwak said they expect that the synergy between DDS expertise and Takeda’s strength in pharmaceutical research and development will lead to RNAi therapeutics of high added-value.